华森制药 2023 上半年非经营性资金占用及其他关联资金往来情况汇总表 编制单位：重庆华森制药股份有限公司 ②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表非经营性占用部分 单位：万元 | 非经营性 | | 占用方与上市 | 上市公司核 | 2023 | 年期初占 | 2023 | 上半年占用 | 2023 上半年占 | 2023 | 上半年 | 2023 | 上半 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | 资金占用方名称 | 公司 | 算的会计科 | 用资金余额 | | 累计发生金额 | | 用资金的利息 | | 偿还累计发 | 年期末占用 | | 原因 | 占用性质 | | | | 的关联关系 | 目 | | | | （不含利息） | （如有） | | 生金额 | 资金余额 | | | | | 控股股东、实际 控制人及其附属 | | | | | | | | | | | | | | ...

证券代码：002907 证券简称：华森制药 公告编号：2023-034 重庆华森制药股份有限公司 关于获得八味芪龙颗粒药品补充申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的关于八味芪龙颗粒的《药品补充申 请批准通知书》，将变更八味芪龙颗粒药品说明书中安全性等内容。现就相关情 况公告如下： 一、药品基本信息 | 药 | 品 | 通 | 用 名 | 称：八味芪龙颗粒 | | --- | --- | --- | --- | --- | | 剂 | | | | 型：颗粒剂 | | 注 | 册 | | 分 | 类：中药 | | 规 | | | | 格：每袋装 6g | | 受 | | 理 | | 号：CYZB2301195 | | 通 | 知 | 书 | 编 | 号：2023B03975 | | 原 | | | 药 品 批 准 文 号：国药准字 | Z20130002 | | | | | 药 品 注 册标准编号：YBZ00082013 | ...

证券代码：002907 证券简称：华森制药 公告编号：2023-033 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝20150018），本次变更主要涉 及增加生产场地。具体情况如下： 一、变更内容 甘桔冰梅片（国药准字 Z20026258）生产场地增加"重庆市荣昌区工业园区一 车间片剂生产线"，本次变更伴随或引发关联变更的，企业需按照有关法律法规要 求完成关联变更的批准、备案后实施或报告。 *** 二、变更后的《药品生产许可证》具体内容 企 业 名 称：重庆华森制药股份有限公司 许可证编号：渝 20150018 社 会 信 用 代 码：915002262038944463 分类码：AhzyBhzChDh 注 册 地 址：重庆市荣昌区工业园区 法定代表人：游洪涛 企业负责人：游洪涛 质量负责人：邓林 质量受权人：王茜 生产负责人：周帮建 有 效 期 至：2025 年 11 月 09 日 ...

证券代码：002907 证券简称：华森制药 公告编号：2023-032 重庆华森制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况的说明 重庆华森制药股份有限公司（以下简称"公司"）股票（证券简称：华森制 药，证券代码：002907）于 2023 年 8 月 8 日、8 月 9 日连续两个交易日内收盘 价涨幅偏离值累计偏离 21.98%。根据《深圳证券交易所交易规则》的有关规定， 属于股票交易异常波动情况。 二、对重要问题的关注、核实情况的说明 （一）经自查，公司不存在违反信息公平披露的情形。 （二）公司 2023 年半年度报告预约披露时间为 2023 年 8 月 22 日。目前 2023 年半年度报告正处于编制阶段，相关财务数据未向第三方提供。按照《深圳证券 交易所股票上市规则》等相关规定要求，公司不存在需要披露业绩预告的情形。 （二）公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生 较大影响的未公开重大信息。 （三）近期公司生产经营情况正常，公司已披露的经营情况、内外部经营环 境未发 ...

Business Performance and Growth - The company's five exclusive traditional Chinese medicine (TCM) products, including Ganju Bingmei Tablets and Tongxie Ning Granules, grew by 17% in 2022 [2] - The company has established a "3-3-3" pipeline strategy, aiming to initiate, submit, and launch at least three new products annually [2] - The company expects to launch at least three new drug varieties annually over the next five years, providing stable profit increments [6] Product Development and Innovation - The company has four self-developed Class 1.1 innovative oncology drugs in the pipeline, covering various solid tumors [4] - Two oncology projects are nearing the PCC stage, with IND-enabling studies expected by the end of 2023 [5] - The company has successfully challenged its first generic drug patent and achieved expected results in a high-variability generic drug pre-BE trial [5] Market Expansion and Strategy - The company has launched its own brand "Quchang" for Orlistat Capsules, which is in the market introduction phase [2] - The company has entered the special medical food (FSMP) market, with three FSMP projects in the pilot stage [3] - The company has built the first FSMP production line in the Sichuan-Chongqing region and expects to obtain the first FSMP production license within three years [3] Health and Wellness Products - The company has introduced the "Yanpin Senhuo" series of health products, including Hawthorn Chicken Gizzard Soft Candy and Yuan Ye Tea, which have shown positive market response [4] - The company is leveraging its pharmaceutical expertise to expand into the health and wellness consumer market, aiming to find new growth points [4] Regulatory and Quality Assurance - The company underwent FDA cGMP international certification inspection in the first half of 2023 and is awaiting results [4] - Passing cGMP certification will enable the company to internationalize its production quality and open up capacity for CMO and CDMO businesses [4] Financial Outlook - The company is confident in achieving revenue and net profit growth in 2023, with hospital terminal diagnostics returning to normal levels [6] - The company plans to deepen its presence in the health and wellness consumer market through new media platforms like TikTok and Xiaohongshu to drive sales growth [6]

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|----------------------------------| | | 特定对象调研 | | | 媒体采访 | | 投资者关系活动类别 | □新闻发布会 | | | □现场参观 | | | □其他 | | | 上海承风金萍私募基金管理有限公司 | | | 上海照友投资管理有限公司 | | | 上海掌未资产管理有限公司 | | 参与单位名称及 | 浙商证券 刘森 | | 人员姓名 | 东北证券 王宁 李天赐 | | | 广州圆石投资 曹丹丹 | | | 上海炬诚资产管理有限公司 | | | 个人投资者 罗亚军 | | 时间 | 2023 年 5 月 24 日 | | 地点 | 公司 3 楼会议室 | | | 周智如（证券事务代表） | | 上市公司接待人姓名 | | | | 黄强燕（证券事务专员） | 一、公司在遵守信息披露制度的前提下，介绍公司经营业 绩、产品布局、市场开发和生产管理等情况，沟通内容与公司 公告内容一致。 投资者关系活动 二 ...

投资者可登陆"路演中"（http://www.roadshowchina.cn/）预约参与本次2022年 度暨2023年一季度业绩网上说明会。 证券代码：002907 证券简称：华森制药 公告编号：2023-024 重庆华森制药股份有限公司 关于举行2022年度暨2023年一季度业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称 "公司"）《2022年年度报告》全文及 其摘要和《2023年第一季度报告》已于2023年4月28日披露，为便于广大投资者更深 入、全面地了解公司生产经营情况和发展战略，公司拟召开"2022年度暨2023年一 季度业绩说明会"。具体情况如下： 一、会议时间、地点 业绩说明会将于2023年5月16日（星期二）下午15:00～17:00通过网络会议的形 式在"路演中"平台举行。 二、参加人员 董事长游洪涛、副总经理及董事会秘书游雪丹、财务总监彭晓燕、独立董事李 嘉明、证券事务代表周智如（如有特殊情况，参与人员会有调整）。 三、投资者参加方式 四、公开征集问题 为充分尊重投资者，广泛听取投 ...

Financial Performance - The company's operating revenue for 2022 was ¥785,182,813.58, a decrease of 7.20% compared to ¥846,141,123.48 in 2021[20]. - Net profit attributable to shareholders for 2022 was ¥98,400,635.86, an increase of 7.21% from ¥91,780,358.79 in the previous year[20]. - The net cash flow from operating activities significantly decreased by 84.25% to ¥13,044,979.35 from ¥82,850,659.92 in 2021[20]. - Basic earnings per share for 2022 rose to ¥0.2441, reflecting a 6.69% increase from ¥0.2288 in 2021[20]. - Total assets at the end of 2022 were ¥1,866,666,731.37, up 5.37% from ¥1,771,483,746.10 at the end of 2021[20]. - Net assets attributable to shareholders increased by 27.21% to ¥1,610,389,994.53 from ¥1,265,920,183.66 in 2021[20]. - The company reported a quarterly revenue of ¥223,493,197.21 in Q4 2022, showing a positive trend compared to previous quarters[25]. - The net profit attributable to shareholders in Q4 2022 was ¥25,553,629.45, indicating a recovery from lower profits in earlier quarters[25]. - The company received government subsidies amounting to ¥16,647,330.21 in 2022, an increase from ¥11,272,143.60 in 2021[26]. - The weighted average return on equity for 2022 was 7.36%, slightly down from 7.51% in 2021[20]. Research and Development - The company has established subsidiaries focused on innovative drug research and development, including Pharscin US and Beijing Huason Inno[11]. - The company is involved in a joint venture for innovative drug research with Sichuan University, enhancing its R&D capabilities[11]. - The company is focused on developing new technologies and products to enhance its competitive position in the market[11]. - The company has four self-developed innovative oncology drugs in the pipeline, with potential indications covering various solid tumors[36]. - The company’s R&D investment strategy focuses on high production cost efficiency, rapid R&D speed, and high technical barriers, with established platforms for drug development[36]. - The company has established a high-end formulation technology platform and reverse engineering technology platform, with capabilities in complex controlled-release technologies and solubilization techniques for poorly soluble drugs, covering various disease areas including oncology[42]. - The company has 24 ongoing projects in formulation and raw material drug development, with 11 new projects initiated and 4 drug registration approvals obtained during the reporting period[45]. - The company is actively developing generic drugs, traditional Chinese medicine, and special medical foods, focusing on fast R&D speed, low manufacturing costs, and high technical barriers[45]. - The company aims to continue challenging higher technical difficulties in R&D projects, focusing on innovative drugs, high-end complex formulations, and high-end generics[42]. - The company achieved R&D investment of 93.27 million yuan in 2022, a slight decrease of 0.42% year-on-year, accounting for 11.88% of revenue, with a compound annual growth rate of 33.77% over the past three years[41]. Market Expansion and Strategy - The company is actively expanding its market presence through various subsidiaries and partnerships in the pharmaceutical sector[11]. - The company has established the first special medical food production base in the Sichuan-Chongqing region in June 2022, with three special medical food projects currently in the pilot testing stage[33]. - The company is committed to meeting clinical medication needs and has expanded its operations into the health industry, reflecting a strategic shift towards comprehensive healthcare solutions[33]. - The company is leveraging its strengths in both traditional Chinese medicine and chemical drugs to create a complementary product strategy, enhancing its market position[34]. - The company plans to launch 2-3 new products annually, which is expected to gradually offset the current revenue and profit pressures[40]. - The company aims to launch at least three new products annually, with ongoing projects including the compound omeprazole sodium bicarbonate capsule and various proprietary Chinese medicine products[51]. - The company is expanding its CMO and CDMO business to utilize idle production capacity and reduce costs[53]. - The company plans to enhance its marketing strategies by implementing a "Spark Plan" to strengthen its marketing team and expand into new sales channels, including digital platforms[111]. - The company is actively pursuing market expansion and innovation in drug research and development[130]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[3]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance[135]. - The company has established a sound internal control system to protect the rights of shareholders, especially minority shareholders[134]. - The company has fulfilled its information disclosure obligations in a timely and accurate manner[134]. - The company has implemented a confidentiality and registration system for insider information[134]. - The company has established a comprehensive internal control system to mitigate operational risks and ensure effective management[180]. - The company has not reported any significant internal control deficiencies during the reporting period[181]. - The company has established a dedicated environmental protection organization and has implemented strict management of wastewater, waste gas, noise, and solid waste, all meeting regulatory standards[189]. - The company has obtained ISO 14001 environmental management system certification, valid until December 9, 2023[192]. - The company is committed to adhering to legal regulations and company bylaws in its decision-making processes[156]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 0.70 CNY per 10 shares (including tax) to all shareholders[3]. - The company adopts a stable profit distribution policy, prioritizing cash dividends, with a minimum of 10% of distributable profits allocated for cash dividends in profitable years[165]. - In the last three years, the company has cumulatively distributed cash dividends amounting to at least 30% of the average annual distributable profits[165]. - The company plans to maintain a cash dividend ratio of at least 80% for mature stages without significant capital expenditure, and at least 40% when there are major capital expenditures[165]. - The company has a complete decision-making process for profit distribution, ensuring independent directors and supervisory board involvement[168]. - The company’s profit distribution policy can be adjusted under extraordinary circumstances, such as natural disasters or significant changes in the external operating environment[168]. - The company has implemented a stock incentive plan, granting 1,484,800 restricted stocks at a price of RMB 10.18 per share to 126 incentive objects[171]. - The company has a mechanism in place for small and medium shareholders to express their opinions and protect their rights during profit distribution discussions[168]. Social Responsibility and Community Engagement - The company has been recognized as a "National Advanced Private Enterprise in Employment and Social Security" and was selected as a "Preferred Employer" by Zhaopin in 2021[196]. - The company donated over 1.35 million yuan in special medicines and 300,000 yuan for ambulances to local health institutions during the reporting period[197]. - The company actively participated in poverty alleviation efforts, providing material and financial support to impoverished households, with donations valued at several tens of thousands of yuan[199]. - The company emphasizes a corporate philosophy of responsibility and vitality, focusing on sustainable growth and compliance in governance[193]. - The company has installed a 24-hour online monitoring system for wastewater discharge, becoming a leader in environmental protection among local enterprises[198].

Financial Performance - The company's revenue for Q1 2023 was ¥187,539,020.46, a decrease of 7.61% compared to ¥202,986,418.16 in the same period last year[5] - Net profit attributable to shareholders was ¥30,100,541.89, representing a 2.55% increase from ¥29,350,796.60 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 187.54 million, a decrease of 7.15% compared to CNY 202.99 million in Q1 2022[23] - Net profit for Q1 2023 was CNY 30.10 million, representing an increase of 2.55% from CNY 29.35 million in Q1 2022[24] - Basic earnings per share for Q1 2023 were CNY 0.0721, slightly down from CNY 0.0732 in Q1 2022[25] Cash Flow - The net cash flow from operating activities surged by 177.84% to ¥99,370,005.77, compared to ¥35,765,741.17 in the previous year[5][6] - Total cash inflow from operating activities reached ¥290,551,022.84, compared to ¥172,040,485.28 in the previous period, indicating a growth of about 68.8%[26] - The cash outflow from operating activities was ¥191,181,017.07, up from ¥136,274,744.11, which is an increase of approximately 40.4%[26] - The cash inflow from other operating activities was ¥106,755,418.96, a substantial increase from ¥2,969,665.98 in the previous period, representing a growth of about 3,487.5%[26] - The cash and cash equivalents at the end of the period amounted to ¥547,122,756.10, an increase from ¥472,530,734.89 in the previous period, reflecting a growth of approximately 15.7%[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,937,718,719.54, up 3.81% from ¥1,866,666,731.37 at the end of the previous year[5] - Total liabilities amounted to CNY 299.96 million, up from CNY 256.28 million in the previous year[21] - The equity attributable to shareholders of the parent company was CNY 1.64 billion, an increase from CNY 1.61 billion year-over-year[21] - The total current assets at the end of the reporting period amounted to 1,015,549,219.51, up from 956,949,388.36 at the beginning of the year[19] Expenses - Research and development expenses increased by 58.41% to ¥14,151,767.59, reflecting the company's commitment to innovation[12] - Total operating costs decreased to CNY 151.82 million, down 9.30% from CNY 167.38 million in the previous year[23] - The company reported a decrease in sales expenses to CNY 52.93 million, down from CNY 54.35 million in the previous year[23] - Tax expenses paid surged to 33,294,627.67, marking a 136.31% increase mainly due to higher value-added tax and additional charges[13] Investment Activities - The net cash flow from investing activities was -¥27,858,952.44, a decline from ¥6,881,474.87 in the previous period, indicating a decrease of 505.5%[27] - The company reported a 100% decrease in cash received from investment recoveries, totaling zero, as there were no financial product redemptions during the period[13] - The cash received from investment income dropped by 80.93% to 163,078.61, primarily due to the absence of financial product redemptions[13] - The company reported a total cash outflow for investing activities of ¥28,022,031.05, down from ¥43,973,675.81 in the previous period, indicating a decrease of approximately 36.2%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,118, with significant holdings concentrated among the top shareholders[15] Strategic Initiatives - The company plans to gradually offset the negative impact on revenue from the chemical drug segment with new product launches and participation in national procurement[5]